Judy Reinsdorf has over 15 years of experience as a C-suite executive and general counsel leading global teams in complex, multinational companies and diverse industries. After retiring from her general counsel role, Reinsdorf embarked on a board career in which she leverages her governance, risk management, and mergers-and-acquisitions skill sets. At Alexion Pharmaceuticals, a $6 billion biopharmaceutical company, she chaired the nominating and corporate governance committee and was a member of the audit and finance committee until the company was sold in 2021 to AstraZeneca. From 2013 to 2019, Reinsdorf was a director of Dun & Bradstreet, a $2 billion commercial data and analytics company, where she chaired the nominating and governance committee and served on the audit committee and compensation and benefits committee before the company was sold to private equity in a $6.9 billion transaction. In 2021, Reinsdorf joined the boards of EnPro Industries (NYSE: NPO), an industrial technology company, and Nurix Therapeutics (NASDAQ: NRIX), a clinical stage biopharmaceutical company. She chairs the nominating and corporate governance committee at EnPro Industries. Reinsdorf was also an independent director on the board of Cornerstone Building Brands (NYSE: CNR) until the sale of the company to its largest shareholder in the third quarter of 2022.

Reinsdorf served as executive vice president and general counsel of Johnson Controls, a Fortune Global 500 leader in building products, technologies, software, and services, after the 2016 merger with Tyco International. From 2007 to 2016, she was executive vice president and general counsel of Tyco during a multi-year transformation of the $37 billion industrial conglomerate executing three public company spin-offs and numerous acquisitions and divestitures. During her tenure, Reinsdorf and her team resolved sensitive Foreign Corrupt Practices Act and securities-enforcement matters with the US Securities and Exchange Commission and the US Department of Justice and built a world-class compliance program. Before joining Tyco as general counsel, she served as general counsel of C.R. Bard, a $2 billion medical device company. Reinsdorf previously worked as associate general counsel at Pharmacia Corp. until the merger with Pfizer in 2002.

Reinsdorf is a member of NACD New Jersey Board of Directors and is also a member of the advisory board of Teach for America New Jersey. In 2019, Reinsdorf was named to WomenInc. Magazine’s 2019 Most Influential Corporate Directors list. Reinsdorf recently received her NACD Directorship Certification.